Fezolinetant is the first NK3 antagonist which has been optimized for use in women’s health, and is being developed for sex-hormone related disorders such as endometriosis, polycystic ovarian syndrome and uterine fibroids. ESN-364 is an oral available small molecule which, due to its unique mechanism of action, allows modulation of the hypothalamic-pituitary gonadal axis with a selective action on hormones relevant to disease. As such, the agent is expected to have greater tolerability than competing products which target GnRH.
|Cas Registry Number||1629229-37-3|
|New Molecular Entity||Yes|
|Mechanism Of Action||Neurokinin-3 (NK-3) receptor antagonist|
|Who Atc Codes||G02 (Other Gynecologicals), G04C (Drugs Used In Benign Prostatic Hypertrophy)|
|Ephmra Codes||G2 (Other Gynaecologicals), G4C (BPH (Benign Prostatic Hypertrophy) Products)|